Is Soleno Therapeutics Inc (SLNO) overvalued? · P/E 27, $2.76B cap
Soleno Therapeutics Inc (SLNO) is a biotechnology company listed on NASDAQ.
This page asks whether Soleno Therapeutics Inc (SLNO) looks expensive on cached numbers — not a short thesis.
No cached income statement for SLNO, so there is no earnings base to call rich or cheap.
SLNO currently screens at market cap $2.76B and trailing P/E 27.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SLNO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SLNO stock page for the full model, not this heading.
Not investment advice.